Mode
Text Size
Log in / Sign up
Phase 4 Completed N=60 Randomized Double-blind Treatment

Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast Surgery

Source: ClinicalTrials.gov NCT02905149 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: Total Opioid Usage — 18.5; 30 milligrams — p=< 0.05
◆ Published Evidence
Established
44citations · ~6 / year
Interfascial block at the serratus muscle plane versus conventional analgesia in breast surgery: a randomized controlled trial.
Regional anesthesia and pain medicine · 2019 · Likely link

Summary

The purpose of this project is to evaluate the analgesic efficacy of a regional anesthesia technique ( interfascial block at the serratus muscle) performed in patient undergoing breast surgery and the effect of this technique on postoperative analgesia.

Linked Publications

  • Interfascial block at the serratus muscle plane versus conventional analgesia in breast surgery: a randomized controlled trial.
    Regional anesthesia and pain medicine · 2019 · 44 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Opioid Usage
18.5; 30 < 0.05 sig
SECONDARY
Pain at Rest and Coughing
4; 6; 0; 0; 1; 1
SECONDARY
Time to First Opioid Administration on the Ward
7.95; 2.9
SECONDARY
Presence of Opioid Related Complications
0; 0

Eligibility Criteria

Inclusion Criteria

  • Patients older than 18 years, undergoing oncological surgery and/or breast reconstruction surgery whose pathology and surgical intervention supose at least a 24 hours hospital admission

Exclusion Criteria

  • ASA Physical Status Classification System- IV.- Morbid obesity (Body mass index >40). -Impossibility of anatomical structures ultrasound identification in a satisfactory way (there can be no distinction in the interfascial plane between serratus and pectoral muscle). -Opioids treatment before surgery. Sepsis and/or infection at the puncture site.
  • Haemostasis disorders. - Allergy to any of the drugs used in the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02905149) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search